Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 16 Sep 2024 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. By: Wellington Management Company LLP, as Investment Adviser By: /s/ Jennifer C. Boylan, Authorized Signatory
Issuer symbol
ZBIO
Transactions as of
16 Sep 2024
Net transactions value
$0
Form type
4
Filing time
18 Sep 2024, 17:16:21 UTC
Previous filing
12 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZBIO Common Stock Conversion of derivative security +180,635 180,635 16 Sep 2024 Direct F1
transaction ZBIO Common Stock Conversion of derivative security +420,271 +233% 600,906 16 Sep 2024 Direct F1, F2
transaction ZBIO Common Stock Conversion of derivative security +200,718 +33% 801,624 16 Sep 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZBIO Series A Convertible Preferred Stock Conversion of derivative security -1,568,480 -100% 0 16 Sep 2024 Common Stock 180,635 Direct F1
transaction ZBIO Series B Convertible Preferred Stock Conversion of derivative security -3,649,263 -100% 0 16 Sep 2024 Common Stock 420,271 Direct F2
transaction ZBIO Series C Convertible Preferred Stock Conversion of derivative security -1,742,858 -100% 0 16 Sep 2024 Common Stock 200,718 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F2 On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
F3 On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.